Tema Neuroscience and Mental Health ETF Rating $22.67 -0.48 (-2.09%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Neuroscience and Mental Health ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.MNTL Aggregate RatingModerate Buy 2.84Holdings in MNTL have an aggregate rating of Moderate Buy based on 607 analyst ratings issued in the past year covering 39 companies (91.6% of the portfolio).MNTL Aggregate Price Target$22.67High Prediction$22.67Average Prediction$22.67Low Prediction$22.67Holdings in MNTL have an aggregate price target of $22.67 and a range of $22.67 to $22.67 covering 39 companies (91.6% of the portfolio).MNTL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy15 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Neuroscience and Mental Health ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 39 MNTL Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings10.23%VRTXVertex Pharmaceuticals$458.86-0.3%4.6563 of 5 stars2.57$515.04 12.2%30Positive NewsAnalyst Revision7.86%REGNRegeneron Pharmaceuticals$523.38+0.3%4.9038 of 5 stars2.85$836.48 59.8%26Positive NewsAnalyst Revision5.76%ALNYAlnylam Pharmaceuticals$306.76+0.7%4.2821 of 5 stars2.77$319.58 4.2%26Positive NewsAnalyst Forecast5.13%ARGXargenx$581.98-0.8%3.6647 of 5 stars3.05$709.18 21.9%22Analyst Forecast4.82%TEVATeva Pharmaceutical Industries$17.27-2.5%4.1314 of 5 stars3.20$24.44 41.6%104.78%NBIXNeurocrine Biosciences$124.88-0.1%4.8979 of 5 stars2.86$162.00 29.7%22Analyst Revision4.08%CRNXCrinetics Pharmaceuticals$31.78-1.2%3.5619 of 5 stars2.91$74.56 134.6%11Positive NewsAnalyst Revision4.07%LLYEli Lilly and Company$823.90+1.5%4.9022 of 5 stars2.76$1,011.37 22.8%21Positive NewsAnalyst Revision3.25%BIIBBiogen$131.72-0.4%4.6977 of 5 stars2.38$188.19 42.9%32Trending NewsAnalyst Forecast3.10%SYKStryker$381.72+0.3%4.9274 of 5 stars2.79$427.30 11.9%19Positive News2.86%IONSIonis Pharmaceuticals$35.50-0.3%4.4512 of 5 stars2.65$56.83 60.1%20Analyst Forecast2.79%CPRXCatalyst Pharmaceuticals$23.75-2.2%4.7907 of 5 stars3.25$32.83 38.2%8Gap Down2.56%MDTMedtronic$88.43-0.1%4.6476 of 5 stars2.56$97.00 9.7%16Positive NewsShort Interest ↓2.51%AXSMAxsome Therapeutics$105.22-1.0%4.7089 of 5 stars3.06$172.33 63.8%16Trending NewsAnalyst ForecastInsider TradeAnalyst Revision2.29%ACADACADIA Pharmaceuticals$21.73-0.1%3.2643 of 5 stars2.69$26.79 23.3%162.16%DNLIDenali Therapeutics$14.63-2.0%4.3448 of 5 stars3.06$33.71 130.4%17Positive NewsAnalyst RevisionGap Down1.94%DXCMDexCom$82.92+0.1%4.7695 of 5 stars2.95$98.32 18.6%211.91%XENEXenon Pharmaceuticals$32.92+0.4%3.5723 of 5 stars3.00$54.82 66.5%12Options VolumeAnalyst Revision1.87%ALKSAlkermes$30.03-2.5%4.7022 of 5 stars2.77$38.85 29.4%13Insider Trade1.85%JAZZJazz Pharmaceuticals$109.43-0.8%4.9669 of 5 stars2.92$184.00 68.2%13Analyst Forecast1.73%PENPenumbra$256.98+1.4%4.6562 of 5 stars2.88$302.40 17.7%171.70%RNAAvidity Biosciences$31.37-2.4%2.1343 of 5 stars3.07$67.33 114.6%15Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap Down1.64%OPCHOption Care Health$31.69-0.6%4.0099 of 5 stars2.88$35.50 12.0%8Positive News1.52%SRRKScholar Rock$32.81-1.5%4.4108 of 5 stars3.14$42.67 30.0%7Positive News1.47%PTCTPTC Therapeutics$51.25+0.5%4.3369 of 5 stars2.64$63.75 24.4%14Analyst Revision0.88%IMVTImmunovant$15.70-1.5%1.5451 of 5 stars2.90$38.33 144.2%10Positive NewsAnalyst Revision0.83%TALKTalkspace$2.91-3.2%3.9025 of 5 stars3.00$4.50 54.9%7Gap Down0.77%SRPTSarepta Therapeutics$36.84-1.3%4.7684 of 5 stars2.87$122.61 232.8%230.74%NTLAIntellia Therapeutics$8.28-0.9%4.6044 of 5 stars2.67$34.95 322.4%21Analyst Revision0.74%DAWNDay One Biopharmaceuticals$6.64-0.7%1.6242 of 5 stars3.13$30.57 360.4%80.65%ACHCAcadia Healthcare$22.08-0.2%4.6074 of 5 stars2.60$47.94 117.2%100.62%BHVNBiohaven$15.35-1.6%3.0207 of 5 stars3.07$59.46 287.5%15Short Interest ↑Analyst Revision0.58%DYNDyne Therapeutics$14.42-0.3%2.7064 of 5 stars3.00$44.93 211.7%15Positive NewsAnalyst ForecastGap Down0.51%VYGRVoyager Therapeutics$3.35-7.1%4.4238 of 5 stars3.13$13.39 300.3%8Analyst RevisionGap Down0.46%PRTAProthena$5.06-0.2%3.8221 of 5 stars2.33$31.50 522.7%9Positive NewsShort Interest ↓Analyst Revision0.42%PRAXPraxis Precision Medicines$44.91-0.3%2.616 of 5 stars2.80$109.90 144.7%10Analyst Forecast0.25%SLDBSolid Biosciences$4.59+0.1%3.9025 of 5 stars3.23$14.90 224.9%13Positive NewsAnalyst RevisionGap Down0.15%RAPPRapport Therapeutics$11.30+1.4%1.98 of 5 stars3.00$32.67 189.1%4Positive News0.14%ARVNArvinas$7.40-2.3%3.9051 of 5 stars2.55$20.29 174.4%22Analyst RevisionGap Down This page (NASDAQ:MNTL) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Neuroscience and Mental Health ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Neuroscience and Mental Health ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
